中文名: ARS Pharmaceuticals, Inc. 公司名称: ARS Pharmaceuticals, Inc. 所属行业: 健康科技 / 主要药品 交易所: 纳斯达克交易所 股票分析 最近更新于 2025-05-08 3 超过36%的股票 行业排名 122/308 市场排名 3487/5416 机构预测 当前价 $13.490 目标均价 $31.60 最高目标价 $40.00 最低目标价 ...
Get real-time ARS Pharmaceuticals (SPRY) stock price quotes, analyst insights, forecasts, news, and information you need to help your stock trading and investing.
SPRY Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced +59.57% ARS Pharmaceuticals, Inc. price and volume Combination chart with 2 data series. Chart represents ARS Pharmaceuticals, Inc. price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart...
关于ARS Pharmaceuticals公司 ARS Pharmaceuticals Inc是一家生物制药公司,专注于开发用于紧急治疗 I 型过敏反应(包括过敏反应)的新型、潜在全新候选产品 neffy。 neffy是一种专有的肾上腺素组合物,含有一种叫做intraail的吸收促进剂,这使得neffy能够以小剂量、易于携带、易于使用、快速给药和可靠的鼻腔喷雾剂提供像注射...
瑞杰金融维持ARS Pharmaceuticals(SPRY.US)买入评级,维持目标价32美元 瑞杰金融分析师Ryan Deschner维持$ARS Pharmaceuticals(SPRY.US)$买入评级,维持目标价32美元。根据TipRanks数据显示,该分析师近一年总胜率为47.6%,总平均回报率为-2.4%。提示: TipRanks为独立第三方,提供金融分析师的分析数据,并计算分析师推荐的平均...
ARS Pharmaceuticals, Inc. - Common Stock(SPRY)14.98+3.17% 瑞杰金融(RJF)145.32-0.79% The European Commission has granted approval to ARS Pharmaceuticals' (NASDAQ:SPRY) EURneffy, an epinephrine nasal spray for the emergency treatment of allergic reactions. ...
Ars Pharmaceuticals Inc (SPRY} {type} Options are used to purchase an option where the goal is to profit from change in the price of the underlying stock.
Ars Pharmaceuticals Inc (SPRY) 11.86 -0.14 (-1.17%) 14:43 ET [NASDAQ] Financial Summary for Thu, Feb 20th, 2025 Notes Alerts Watch Help ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could...
随着neffy在美国推出并进军全球市场,ARS Pharmaceuticals有望实现增长。该公司专注于付款人覆盖范围、儿科应用和非零售机会,这是其应对价值30亿美元的美国肾上腺素市场的战略,同时挖掘额外70亿美元的潜在销售额。凭借稳健的现金状况和战略投资,ARS完全有能力在2025年及以后推动采用和扩大其运营规模。
To track hedge funds' stock portfolios, check out Quiver Quantitative'sinstitutional holdings dashboard. Full Release Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. ...